StemRIM

StemRIM Inventory

The Inventory of StemRIM (4599.T) as of Nov 7, 2026 is 15.21 M JPY. In the previous year, Inventory was 16.72 M JPY — a change of -9.04% (lower).

Inventory

15.21 MJPY

YoY

-9.04%

Last updated:

Inventory of StemRIM is 2026 15.21 M JPY. Inventory of StemRIM was 2025 16.72 M JPY. It decreases by -9.04% lower compared to the previous year.

The StemRIM Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2019
12.65 M JPY
Jan 1, 2020
18.05 M JPY
Jan 1, 2021
12.11 M JPY
Jan 1, 2022
4.35 M JPY
Jan 1, 2023
8.51 M JPY
Jan 1, 2024
29.33 M JPY
Jan 1, 2025
16.72 M JPY
Jan 1, 2026
15.21 M JPY
The StemRIM Inventory history
YEARInventoryYoY
15.21 MJPY-9.04%
16.72 MJPY-43.00%
29.33 MJPY+244.54%
8.51 MJPY+95.81%
4.35 MJPY-64.10%
12.11 MJPY-32.89%
18.05 MJPY+42.69%
12.65 MJPY+22.26%
10.35 MJPY-84.39%
66.29 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

StemRIM Stock analysis

What does StemRIM do? StemRIM, Inc. develops and researches regeneration-inducing medicine based on a new action mechanism to promote functional regeneration and healing of damaged biological tissue. The company's main product is stem cell regeneration-inducing medicine, which delivers therapeutic effects similar to regenerative medicine without requiring living cells or tissues. StemRIM's primary customers are medical institutions and healthcare providers seeking advanced treatment options for tissue repair and regeneration. The company generates revenue through the sale of its stem cell regeneration-inducing medicine to these healthcare segments. StemRIM focuses on research and development of medicines that can restore lost function in biological tissue caused by injury or illness. The firm's product line centers around its stem cell regeneration-inducing medicine, which eliminates the need for using living cells in treatment. This innovative approach targets medical professionals and institutions looking for efficient regenerative solutions. StemRIM's business model relies on selling its patented medicine to healthcare providers for clinical applications. The company's revenue streams come from the commercialization of its stem cell regeneration-inducing medicine, which is designed to provide regenerative therapy without cell-based treatments. StemRIM's target market includes hospitals and medical facilities that require advanced regenerative treatments for patients with tissue damage. The firm's research and development efforts are centered on creating medicines that can promote healing through a novel mechanism, differentiating their product from traditional regenerative medicine approaches. StemRIM is one of the most popular companies on Eulerpool.

Frequently Asked Questions about StemRIM stock

Inventory of StemRIM is 15.21 M JPY in 2026.

Inventory of StemRIM changed from 16.72 M JPY to 15.21 M JPY, representing a -9.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Inventory StemRIM since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's StemRIM historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — StemRIM

All Key Metrics — StemRIM